Adaptimmune And Astellas Team Up For Off-The-Shelf T-Cell Therapies

Could Be Worth $900m

 
• By Kevin Grogan
  
Suit_Battery
Data boost and Astellas Deal Revitalize Adaptimmune • Source: Shutterstock
Scrip Podcast

Have you checked out Scrip podcast?

New episodes every Thursday.

SpotifyApple PodcastsWebsite

More from Immuno-oncology

More from Anticancer